Poseida Therapeutics/PSTX

$3.51

-4.09%
-
1D1W1MYTD1YMAX

About Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s approach to cell and gene therapies is based on its genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. Its P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate with the potential to treat a range of solid tumor indications, including breast and other epithelial-derived cancers. Its product candidate, P-PSMA- ALLO1, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. Its P-CD19CD20-ALLO1 is an allogeneic, CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications.
Ticker
PSTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Mark Gergen
Employees
327
Headquarters
San diego, United States

PSTX Metrics

BasicAdvanced
$349.99M
Market cap
-
P/E ratio
-$1.50
EPS
0.35
Beta
-
Dividend rate

What the Analysts think about PSTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 3 analysts.
298.86% upside
High $20.00
Low $10.00
$3.51
Current price
$14.00
Average price target

PSTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-340.86% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$9.3M
-53.5%
Net income
$-31.7M
15.69%
Profit margin
-340.86%
148.8%

PSTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 19.66%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.39
-$0.45
-$0.32
-$0.35
-
Expected
-$0.23
-$0.45
-$0.53
-$0.29
-$0.39
Surprise
73.33%
0%
-39.39%
19.66%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Poseida Therapeutics stock

Buy or sell Poseida Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing